Literature DB >> 30756208

New Face of Hepatitis C.

Tiffany Wu1, Peter G Konyn2, Austin W Cattaneo2, Sammy Saab3,4,5.   

Abstract

Chronic hepatitis C viral (HCV) infection continues to carry a high burden of disease despite recent and emerging advancements in treatment. The persistently high prevalence of HCV is attributed to the rising opioid epidemic, with a history of injection drug use as the primary risk factor for infection. As a result, the epidemiology of HCV-infected individuals is changing. Previously a disease of "Baby Boomers," males, and non-Hispanic blacks, the new generation of patients with HCV includes younger adults from 20 to 39 years of age, both men and women similarly represented, and non-Hispanic whites. Shifting trends in these demographics may be attributed to the use of injection drugs, which also has suggested impact on fibrosis progression in infected individuals. Awareness of the changing face of HCV is necessary to expand and revise recommendations regarding screening, outreach, and care engagement of infected individuals, in order to best identify patients at-risk for infection.

Entities:  

Keywords:  Diagnosis; Epidemiology; Hepatitis C; Risk factors

Mesh:

Year:  2019        PMID: 30756208     DOI: 10.1007/s10620-019-05511-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  43 in total

1.  Trends in U.S. Drug Overdose Deaths in Non-Hispanic Black, Hispanic, and Non-Hispanic White Persons, 2000-2015.

Authors:  Meredith S Shiels; Neal D Freedman; David Thomas; Amy Berrington de Gonzalez
Journal:  Ann Intern Med       Date:  2017-12-05       Impact factor: 25.391

Review 2.  Methods of transmission of hepatitis C.

Authors:  C J Tibbs
Journal:  J Viral Hepat       Date:  1995       Impact factor: 3.728

3.  Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.

Authors:  Anil G Suryaprasad; Jianglan Z White; Fujie Xu; Beth-Ann Eichler; Janet Hamilton; Ami Patel; Shadia Bel Hamdounia; Daniel R Church; Kerri Barton; Chardé Fisher; Kathryn Macomber; Marisa Stanley; Sheila M Guilfoyle; Kristin Sweet; Stephen Liu; Kashif Iqbal; Rania Tohme; Umid Sharapov; Benjamin A Kupronis; John W Ward; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2014-08-11       Impact factor: 9.079

4.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

5.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

6.  Disparities in hepatitis C virus infection screening among Baby Boomers in the United States.

Authors:  Mona Nili; Lucy Luo; Xue Feng; Jongwha Chang; Xi Tan
Journal:  Am J Infect Control       Date:  2018-07-14       Impact factor: 2.918

7.  Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016.

Authors:  Puja Seth; Lawrence Scholl; Rose A Rudd; Sarah Bacon
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-03-30       Impact factor: 17.586

8.  Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007.

Authors:  Barbara Tempalski; Enrique R Pouget; Charles M Cleland; Joanne E Brady; Hannah L F Cooper; H Irene Hall; Amy Lansky; Brooke S West; Samuel R Friedman
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

9.  Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012.

Authors:  Jon E Zibbell; Kashif Iqbal; Rajiv C Patel; Anil Suryaprasad; Kathy J Sanders; Loretta Moore-Moravian; Jamie Serrecchia; Steven Blankenship; John W Ward; Deborah Holtzman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-08       Impact factor: 17.586

Review 10.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.

Authors:  Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney
Journal:  Lancet Glob Health       Date:  2017-10-23       Impact factor: 26.763

View more
  5 in total

1.  Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study.

Authors:  Douglas Halket; Jimmy Dang; Anuradha Phadke; Channa Jayasekera; W Ray Kim; Paul Kwo; Lance Downing; Aparna Goel
Journal:  J Gen Intern Med       Date:  2022-03-01       Impact factor: 6.473

2.  Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival.

Authors:  Shoshana Adler Jaffe; Orrin Myers; Angela L W Meisner; Charles L Wiggins; Deirdre A Hill; Jean A McDougall
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-12-03       Impact factor: 4.254

3.  Inverse probability weighting for selection bias in a Delaware community health center electronic medical record study of community deprivation and hepatitis C prevalence.

Authors:  Neal D Goldstein; Deborah Kahal; Karla Testa; Igor Burstyn
Journal:  Ann Epidemiol       Date:  2021-04-29       Impact factor: 6.996

4.  Preliminary Screening Results Outside the 1945-1965 Birth Cohort: A Forgotten Population for Hepatitis C?

Authors:  Daniel Winetsky; Jason Zucker; Jacek Slowikowski; Matthew Scherer; Elizabeth C Verna; Peter Gordon
Journal:  Open Forum Infect Dis       Date:  2019-04-10       Impact factor: 3.835

5.  Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.

Authors:  Michael Bobardt; Magnus Joakim Hansson; Patrick Mayo; Daren Ure; Robert Foster; Philippe Gallay
Journal:  PLoS One       Date:  2020-08-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.